CCHT(000661)

Search documents
特宝生物长效生长激素在国内获批 长春高新十年垄断格局被打破
Mei Ri Jing Ji Xin Wen· 2025-05-29 14:19
Core Viewpoint - The approval of Yipeisheng (益佩生), a long-acting growth hormone injection by Tebao Biopharma, marks a significant shift in the long-acting growth hormone market, breaking the decade-long monopoly held by Jinsai Pharmaceutical [2][4]. Company Summary - Tebao Biopharma's Yipeisheng is designed for weekly administration, targeting growth hormone deficiency in children aged three and above, enhancing patient compliance and reducing treatment burden [2][3]. - The company reported a revenue of 2.817 billion yuan in 2024, a year-on-year increase of 34.13%, and a net profit of 828 million yuan, up 49% year-on-year [6]. - The company has five existing products, with Paigebin being the main revenue driver, generating 2.447 billion yuan, accounting for over 80% of total revenue [6]. Industry Summary - The long-acting growth hormone market has been dominated by Jinsai Pharmaceutical for over ten years, with its product "Jinsai Zeng" being the first globally approved long-acting growth hormone [3][4]. - The market for growth hormone treatment in China is significant, with approximately 6.4 million children affected by growth hormone deficiency, indicating a substantial unmet medical need [3]. - The entry of Yipeisheng is expected to intensify competition in the long-acting growth hormone sector, potentially leading to expanded indications and increased market share for long-acting products [4].
长春高新(000661) - 关于公司与专业投资机构共同投资进展暨完成私募投资基金备案登记的公告
2025-05-29 10:46
证券代码:000661 证券简称:长春高新 公告编号:2025-057 长春高新技术产业(集团)股份有限公司 关于公司与专业投资机构共同投资进展 暨完成私募投资基金备案登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记 载、误导性陈述或重大遗漏。 为进一步提升产业投资能力,提高资金使用效率,长春高新技术产业(集团) 股份有限公司(以下简称"公司")于 2024 年 10 月 24 日召开第十一届董事会第 五次会议审议通过了《关于公司拟与专业投资机构共同投资设立合伙企业的议案》, 同意公司作为有限合伙人与中信建投资本管理有限公司(以下简称"中信建投资 本")、长春长发私募基金管理有限公司及其他有限合伙人共同出资成立投资基 金。具体内容详见公司于 2024 年 10 月 26 日披露的《关于公司拟与专业投资机构 共同投资设立合伙企业的公告》(公告编号:2024-107)。 近日,公司收到基金管理人通知,该基金已在中国证券投资基金业协会完成 备案手续,取得了《证券公司私募投资基金备案证明》,备案信息如下: 基金名称:长春星河润信创业投资中心(有限合伙) 管理人名称:中信建投资本管理有限 ...
生物疫苗ETF(159657)涨超2%,ASCO大会召开在即
Xin Lang Cai Jing· 2025-05-29 06:51
Group 1 - The National Vaccine and Biotechnology Index (980015) has seen a strong increase of 2.39% as of May 29, 2025, with notable gains in constituent stocks such as Zhaoyan New Drug (603127) up 9.99%, Yifan Pharmaceutical (002019) up 9.17%, and Dizhe Pharmaceutical (688192) up 8.73% [1] - The Biovaccine ETF (159657) rose by 2.28%, with the latest price reported at 0.63 yuan [2] - The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting will take place from May 30 to June 3, 2025, in Chicago, showcasing the development of oncology research in China, with over 70 studies from Chinese scholars selected for presentation [2] Group 2 - The top ten weighted stocks in the National Vaccine and Biotechnology Index (980015) as of April 30, 2025, include Fosun Pharma (600196), Changchun High-tech (000661), and others, collectively accounting for 63.18% of the index [3] - The Biovaccine ETF closely tracks the National Vaccine and Biotechnology Index, which consists of 50 companies involved in the biotechnology industry, reflecting the overall performance of quality listed companies in the sector [2]
生长激素龙头的“生长痛”:降价、竞品两头夹击,转型成效尚待观察
Mei Ri Jing Ji Xin Wen· 2025-05-29 06:18
Core Viewpoint - The leading companies in the growth hormone sector, Changchun High-tech and Anke Bio, are facing declining revenues and are seeking new growth avenues through diversification into other therapeutic areas [1][2][3]. Group 1: Company Performance - Both Changchun High-tech and Anke Bio reported a decline in revenue and net profit for 2024, with Changchun High-tech experiencing its first annual revenue drop in nearly 20 years, showing a 5.66% decrease in revenue and a 44.95% drop in net profit for Q1 2025 [2][3]. - Anke Bio's revenue and net profit also fell by over 10% in the previous year, with a 4% decline in both metrics for Q1 2025 [2][3]. Group 2: Market Dynamics - The growth hormone market in China has expanded significantly, from $600 million in 2018 to $1.7 billion in 2022, capturing 34% of the global market share, surpassing the United States [2]. - The introduction of price-cutting measures in 2022 has pressured the revenues of the two leading companies, leading to a contraction in their growth hormone business [2][3]. Group 3: Product Development and Diversification - Changchun High-tech and Anke Bio are both attempting to diversify their product lines beyond growth hormones, with Changchun High-tech planning to expand into pediatrics, women's health, and anti-aging sectors [4][5]. - Changchun High-tech's subsidiary, GenSci, has seen over 76% of its revenue coming from growth hormones, while Anke Bio's growth hormone sales account for nearly 70% of its total revenue [3]. - Both companies have initiated clinical trials for new products, with Changchun High-tech focusing on innovative drugs and Anke Bio expanding into antiviral and oncology treatments [5].
上市公司高管去年最高年薪超4000万,药企高管领跑排行榜
Nan Fang Du Shi Bao· 2025-05-29 04:20
Core Insights - The report titled "China Entrepreneur Value Report (2025)" reveals the salary rankings of executives in A-share listed companies for 2024, indicating a slight decline in average executive salaries by 1.29% compared to the previous year, although the decline is less severe than in prior years [1][5] - The financial industry continues to lead in executive compensation, followed by wholesale and retail, while the real estate sector has seen a significant drop in its ranking from fifth in 2023 to twelfth in 2024 [1][2] Executive Salary Rankings - The highest-paid executive in 2024 is Li Ge, Chairman and CEO of WuXi AppTec, with an annual salary of 41.8 million yuan, slightly down from 41.9686 million yuan in 2023 [2][4] - Other top earners include executives from major pharmaceutical companies and well-known brands, with several executives earning over 10 million yuan annually [2][4] Salary Trends by Position - The average salary for chairpersons of listed companies in 2024 is 1.3394 million yuan, an increase of 1.70% from the previous year, while the average salary for general managers (not serving as chairpersons) decreased by 2.43% to 1.3051 million yuan [4] - Independent directors' average annual compensation is reported at 102,900 yuan, down 9.69% from the previous year [4] Stock Incentive Plans - The report indicates a decline in the total number of stock incentive plans announced in 2024, with 610 plans, an 8.41% decrease from 2023, although multi-period incentive plans have increased from 53.90% in 2023 to 61.6% in 2024 [5][6] - The total number of broad stock incentive plans, including employee stock ownership plans and stock options, rose by 2.03% to 854 plans in 2024 [6] Regional Distribution of Incentive Plans - Coastal cities, particularly in East and South China, have a significantly higher number of stock incentive plans compared to Southwest and Northeast regions, with Guangdong province leading with 125 plans, accounting for 20.49% of the total [6] - The report emphasizes that stock incentives have become a crucial tool for optimizing the overall compensation system of A-share listed companies [6]
长春高新技术产业(集团)股份有限公司 关于子公司GenSci128片新药临床试验申请 获得美国食品药品监督管理局批准的公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-05-28 23:18
Core Viewpoint - The company has received FDA approval for clinical trials of GenSci128 tablets, a targeted therapy for patients with TP53 Y220C mutation in advanced or metastatic solid tumors [1][2]. Group 1: Drug Information - Product Name: GenSci128 tablets - Application: Clinical trial approval in the US - Acceptance Number: IND 174059 - Applicant: Changchun JinSai Pharmaceutical Co., Ltd. - Approval Conclusion: Permission granted for clinical trials in the US - Indication: Local advanced or metastatic solid tumors with TP53 Y220C mutation [1]. Group 2: Drug Mechanism and Development - GenSci128 is a class 1 new chemical drug designed as a selective reactivator for TP53 Y220C mutation, aiming to restore the normal conformation and function of the mutated protein [2]. - Preclinical data indicates that GenSci128 has good efficacy and safety [2]. - The drug has also been approved for clinical trials in China for the same indication [2]. Group 3: Company Impact - Successful progress in clinical trials could help the company expand its business structure, optimize product offerings, and enhance core competitiveness [3]. - The company will actively promote the research and development of this project and comply with disclosure obligations regarding project progress [4].
长春高新(000661) - 2025年5月27日、5月28日投资者关系活动记录表
2025-05-28 10:26
Group 1: Company Strategy and Development - The company aims to establish a globally influential biopharmaceutical group, focusing on innovation in the health sector and internationalization as a guiding strategy [2] - The company will enhance innovation investment and cooperation to cultivate new economic growth points, while also improving brand value and operational efficiency [2][3] - The company emphasizes a principle of "optimizing existing resources, enhancing new growth, and strengthening research and development" [2] Group 2: Product Development and Market Position - The company has approved 12 indications for its growth hormone products, maintaining a leading market share in China [4][5] - The long-acting growth hormone has undergone extensive clinical trials, demonstrating safety and efficacy with over 10,000 real-world applications [4] - The company is actively promoting its growth hormone products through educational initiatives to enhance understanding among healthcare professionals and patients [5] Group 3: Financial Performance and Investor Relations - As of April 30, 2025, the company has repurchased 3,894,517 shares, accounting for 0.95% of its total share capital, with a total transaction amount of approximately RMB 399.99 million [15] - The company is committed to optimizing resource allocation while controlling costs to ensure a balance between research investment and output efficiency [13][14] - The company will continue to enhance transparency in investor relations through various communication channels [15] Group 4: Research and Development - The company is focused on high-quality development through innovation, with plans to explore cutting-edge technologies and establish an intelligent research platform [10][14] - The company is preparing for European market applications for several products, including short-acting growth hormone and other innovative drugs [8] Group 5: Real Estate and Asset Management - The company is actively managing its real estate segment, focusing on inventory reduction and transitioning to a light asset operation model [11][12] - The real estate division is involved in urban renewal projects, integrating with the pharmaceutical sector to enhance resource utilization [11]
长春高新:子公司GenSci128片新药临床试验申请获得美国FDA批准
news flash· 2025-05-28 09:50
Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Jinsai Pharmaceutical, received approval from the US FDA to conduct clinical trials for GenSci128 tablets, a selective reactivator targeting the TP53 Y220C mutation for treating locally advanced or metastatic solid tumors carrying this mutation [1] Group 1 - GenSci128 tablets have already been approved for clinical trials in China [1] - Successful progress in the clinical trial application will help the company broaden its business structure and optimize its product portfolio [1] - The development of GenSci128 is expected to enrich and enhance the strategic product line layout, thereby improving the company's core competitiveness [1]
沪深300制药与生物科技指数报7798.06点,前十大权重包含新和成等
Jin Rong Jie· 2025-05-28 08:07
Group 1 - The Shanghai Composite Index opened high and fluctuated, with the CSI 300 Pharmaceutical and Biotechnology Index reported at 7798.06 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has increased by 4.26% in the past month, 2.71% in the past three months, and 4.75% year-to-date [1] - The CSI 300 Index samples are categorized into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten weights in the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (25.23%), WuXi AppTec (16.45%), Pian Zai Huang (6.51%), Yunnan Baiyao (5.3%), Kelun Pharmaceutical (5.04%), East China Pharmaceutical (3.91%), New Horizon (3.59%), Changchun High-tech (3.57%), Shanghai Raist (3.34%), and Fosun Pharmaceutical (3.18%) [1] - The market share of the CSI 300 Pharmaceutical and Biotechnology Index is 63.57% from the Shanghai Stock Exchange and 36.43% from the Shenzhen Stock Exchange [2] - The industry composition of the index includes: Chemical drugs (43.24%), Pharmaceutical and Biotechnology services (21.56%), Traditional Chinese medicine (18.83%), and Biological drugs (16.37%) [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made when the CSI 300 Index samples are modified [2] - Special events affecting sample companies may lead to changes in industry classification and subsequent adjustments to the CSI 300 industry index samples [2]